<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40933018</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2604-7276</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>REC, interventional cardiology</Title><ISOAbbreviation>REC Interv Cardiol</ISOAbbreviation></Journal><ArticleTitle>Left atrial appendage occlusion plus oral anticoagulation in stroke patients despite ongoing anticoagulation: rationale and design of the ADD-LAAO clinical trial.</ArticleTitle><Pagination><StartPage>140</StartPage><EndPage>145</EndPage><MedlinePgn>140-145</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/RECICE.M25000507</ELocationID><Abstract><AbstractText Label="INTRODUCTION AND OBJECTIVES" NlmCategory="UNASSIGNED">The prevalence of atrial fibrillation and the number of patients experiencing ischemic strokes despite oral anticoagulation (OAC) are both on the rise, which presents a significant challenge due to the absence of clear and uniform treatment recommendations for these patients. To date, there is no formal combination merging into a high anticoagulant efficacy profile while keeping a low bleeding risk. Transcatheter left atrial appendage occlusion (LAAO) in combination with OAC might provide a balance between safety and efficacy. The objective of this study is to evaluate whether, in ischemic stroke patients, despite anticoagulation, the combination of LAAO plus long-term anticoagulation-direct oral anticoagulants or vitamin K antagonist when indicated-is associated with a lower rate of recurrent cardioembolic events at 12 months vs the optimal medical therapy recommended by the neurologist.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A total of 380 patients with ischemic stroke despite OAC will be included. Patients will be randomized on a 1:1 ratio to receive the optimal medical therapy (control) or the combination of LAAO plus OAC or OAC. The primary endpoint of the study will be the occurrence of a cardioembolic event-ischemic stroke or arterial peripheral embolism-within the first 12 months after inclusion.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This study is one of the first randomized clinical trials to compare the LAAO plus OAC combination and optimal medical therapy in patients who have experienced ischemic strokes despite being on OAC. If results confirm the superiority of LAAO plus OAC, it could lead to a paradigm shift in treatment guidelines for these patients.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2025 Sociedad Espa&#xf1;ola de Cardiolog&#xed;a.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amaro</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departamento de Neurolog&#xed;a, Hospital Cl&#xed;nic de Barcelona, Barcelona, Espa&#xf1;a Departamento de Neurolog&#xed;a Hospital Cl&#xed;nic de Barcelona Barcelona Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz-Gonz&#xe1;lez</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Departamento de Cardiolog&#xed;a, Hospital Universitario de Salamanca, Salamanca, Espa&#xf1;a Departamento de Cardiolog&#xed;a Hospital Universitario de Salamanca Salamanca Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Est&#xe9;vez-Loureiro</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departamento de Cardiolog&#xed;a, Hospital Universitario &#xc1;lvaro Cunqueiro, Vigo, Pontevedra, Espa&#xf1;a Departamento de Cardiolog&#xed;a Hospital Universitario &#xc1;lvaro Cunqueiro Vigo Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millan</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Departamento de Cardiolog&#xed;a, Hospital de la Santa Creu i Sant Pau, Barcelona, Espa&#xf1;a Departamento de Cardiolog&#xed;a Hospital de la Santa Creu i Sant Pau Barcelona Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nombela-Franco</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departamento de Cardiolog&#xed;a, Hospital Cl&#xed;nico San Carlos, Madrid, Espa&#xf1;a Departamento de Cardiolog&#xed;a Hospital Cl&#xed;nico San Carlos Madrid Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez-Hospital</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Cardiolog&#xed;a, Hospital Universitari de Bellvitge, Barcelona, Espa&#xf1;a Departamento de Cardiolog&#xed;a Hospital Universitari de Bellvitge Barcelona Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores-Umanzor</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departamento de Cardiolog&#xed;a, Hospital Cl&#xed;nic de Barcelona, Barcelona, Espa&#xf1;a Departamento de Cardiolog&#xed;a Hospital Cl&#xed;nic de Barcelona Barcelona Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Mesonero</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departamento de Neurolog&#xed;a, Hospital Universitario de Salamanca, Salamanca, Espa&#xf1;a Departamento de Neurolog&#xed;a Hospital Universitario de Salamanca Salamanca Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maci&#xf1;eiras</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departamento de Neurolog&#xed;a, Hospital Universitario &#xc1;lvaro Cunqueiro, Vigo, Espa&#xf1;a Departamento de Neurolog&#xed;a Hospital Universitario &#xc1;lvaro Cunqueiro Vigo Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-S&#xe1;nchez</LastName><ForeName>Lluis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departamento de Neurolog&#xed;a, Hospital de la Santa Creu i Sant Pau, Barcelona, Espa&#xf1;a Departamento de Neurolog&#xed;a Hospital de la Santa Creu i Sant Pau Barcelona Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simal</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departamento de Neurolog&#xed;a, Hospital Cl&#xed;nico San Carlos, Madrid, Espa&#xf1;a Departamento de Neurolog&#xed;a Hospital Cl&#xed;nico San Carlos Madrid Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardona</LastName><ForeName>Pere</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departamento de Neurolog&#xed;a, Hospital Universitari de Bellvitge, Barcelona, Espa&#xf1;a Departamento de Neurolog&#xed;a Hospital Universitari de Bellvitge Barcelona Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teruel</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Departamento de Cardiolog&#xed;a, Hospital Universitari de Bellvitge, Barcelona, Espa&#xf1;a Departamento de Cardiolog&#xed;a Hospital Universitari de Bellvitge Barcelona Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cepas-Guill&#xe9;n</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departamento de Cardiolog&#xed;a, Hospital Cl&#xed;nic de Barcelona, Barcelona, Espa&#xf1;a Departamento de Cardiolog&#xed;a Hospital Cl&#xed;nic de Barcelona Barcelona Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arzamendi</LastName><ForeName>Dabit</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Departamento de Cardiolog&#xed;a, Hospital de la Santa Creu i Sant Pau, Barcelona, Espa&#xf1;a Departamento de Cardiolog&#xed;a Hospital de la Santa Creu i Sant Pau Barcelona Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freixa</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Departamento de Cardiolog&#xed;a, Hospital Cl&#xed;nic de Barcelona, Barcelona, Espa&#xf1;a Departamento de Cardiolog&#xed;a Hospital Cl&#xed;nic de Barcelona Barcelona Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>REC Interv Cardiol</MedlineTA><NlmUniqueID>9919033203206676</NlmUniqueID><ISSNLinking>2604-7306</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N Y OBJETIVOS" NlmCategory="UNASSIGNED">La prevalencia de la fibrilaci&#xf3;n auricular y el n&#xfa;mero de pacientes que sufren ictus isqu&#xe9;micos a pesar de recibir anticoagulaci&#xf3;n oral (ACO) est&#xe1;n aumentando. Este incremento representa un importante desaf&#xed;o debido a la ausencia de recomendaciones claras y uniformes sobre el tratamiento de estos pacientes. Hasta la fecha no existe una combinaci&#xf3;n que logre una alta eficacia anticoagulante manteniendo un bajo riesgo de hemorragia. El cierre u oclusi&#xf3;n percut&#xe1;nea de la orejuela izquierda (OI) a&#xf1;adida a la ACO podr&#xed;a ofrecer un equilibrio entre eficacia y seguridad. El objetivo es evaluar si, en pacientes con ictus isqu&#xe9;mico a pesar de recibir ACO, la combinaci&#xf3;n de cierre de la OI y ACO a largo plazo (anticoagulantes orales de acci&#xf3;n directa o bien antagonista de la vitamina K, cuando est&#xe9; indicado) se asocia con una menor incidencia de eventos cardioemb&#xf3;licos recurrentes a los 12 meses, en comparaci&#xf3;n con el mejor tratamiento m&#xe9;dico propuesto por el neur&#xf3;logo.</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">Se incluir&#xe1; a 380 pacientes con ictus isqu&#xe9;mico a pesar de recibir ACO. Los pacientes se aleatorizar&#xe1;n en una proporci&#xf3;n 1:1 al mejor tratamiento m&#xe9;dico (grupo control) o a la combinaci&#xf3;n de cierre de OI y ACO. El objetivo principal del estudio ser&#xe1; la ocurrencia de un evento cardioemb&#xf3;lico (ictus isqu&#xe9;mico o embolia arterial perif&#xe9;rica) dentro de los primeros 12 meses tras la inclusi&#xf3;n.</AbstractText><AbstractText Label="CONCLUSIONES" NlmCategory="UNASSIGNED">Este estudio es uno de los primeros ensayos cl&#xed;nicos aleatorizados que compara la combinaci&#xf3;n de cierre de OI m&#xe1;s ACO con el tratamiento m&#xe9;dico &#xf3;ptimo en pacientes que han sufrido un ictus isqu&#xe9;mico a pesar de estar recibiendo ACO. Si los resultados confirman la superioridad del cierre de OI m&#xe1;s ACO, podr&#xed;a significar un cambio de paradigma en las gu&#xed;as de tratamiento para estos pacientes.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2025 Sociedad Espa&#xf1;ola de Cardiolog&#xed;a.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Direct oral anticoagulation</Keyword><Keyword MajorTopicYN="N">Left atrial appendage occlusion</Keyword><Keyword MajorTopicYN="N">Oral anticoagulation</Keyword><Keyword MajorTopicYN="N">Recurrent stroke</Keyword></KeywordList><CoiStatement>CONFLICTO DE INTERESES: I. Cruz-Gonz&#xe1;lez y X. Freixa son proctors de Abbott Medical, Boston Scientific y Lifetech. R. Est&#xe9;vez-Loureiro y D. Arzamendi lo son de Abbott Medical y Boston Scientific y L. Nombela-Franco de Abbott Medical. El resto de los autores no declararon ning&#xfa;n conflicto de intereses.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40933018</ArticleId><ArticleId IdType="pmc">PMC12418240</ArticleId><ArticleId IdType="doi">10.24875/RECICE.M25000507</ArticleId><ArticleId IdType="pii">2604-7306-recic-7-3-140</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hart RG, Pearce LA, Aguilar MI. Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. <i>Ann Intern Med.</i> 2007;146:857-867.</Citation><ArticleIdList><ArticleId IdType="pubmed">17577005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart RG, Pearce LA, Aguilar MI. Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pubmed">17577005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:a meta-analysis of randomised trials. <i>Lancet.</i> 2014;383:955-962.</Citation><ArticleIdList><ArticleId IdType="pubmed">24315724</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:a meta-analysis of randomised trials. Lancet. 2014;383:955&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">24315724</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. <i>N Engl J Med.</i> 2009;361:1139-1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">19717844</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139&#x2013;1151.</Citation><ArticleIdList><ArticleId IdType="pubmed">19717844</ArticleId></ArticleIdList></Reference><Reference><Citation>Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. <i>N Engl J Med.</i> 2013;369:2093-2104.</Citation><ArticleIdList><ArticleId IdType="pubmed">24251359</ArticleId></ArticleIdList></Reference><Reference><Citation>Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093&#x2013;2104.</Citation><ArticleIdList><ArticleId IdType="pubmed">24251359</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. <i>N Engl J Med.</i> 2011;365:981-992.</Citation><ArticleIdList><ArticleId IdType="pubmed">21870978</ArticleId></ArticleIdList></Reference><Reference><Citation>Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pubmed">21870978</ArticleId></ArticleIdList></Reference><Reference><Citation>Xian Y, O'Brien EC, Liang L, et al. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. <i>JAMA</i>. 2017;317:1057-1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">28291892</ArticleId></ArticleIdList></Reference><Reference><Citation>Xian Y, O'Brien EC, Liang L, et al. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA. 2017;317:1057&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">28291892</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiffge DJ, De Marchis GM, Koga M, et al. Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. <i>Ann Neurol.</i> 2020;87:677-687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383617</ArticleId><ArticleId IdType="pubmed">32052481</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiffge DJ, De Marchis GM, Koga M, et al. Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. Ann Neurol. 2020;87:677&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383617</ArticleId><ArticleId IdType="pubmed">32052481</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinel TR, Branca M, De Marchis GM, et al. Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation. <i>Ann Neurol.</i> 2021;89:42-53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7756294</ArticleId><ArticleId IdType="pubmed">32996627</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinel TR, Branca M, De Marchis GM, et al. Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation. Ann Neurol. 2021;89:42&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7756294</ArticleId><ArticleId IdType="pubmed">32996627</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaghi S, Henninger N, Giles JA, et al. Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke:the IAC study. <i>J Neurol Neurosurg Psychiatry.</i> 2021;92:1062-1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8448925</ArticleId><ArticleId IdType="pubmed">33903185</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaghi S, Henninger N, Giles JA, et al. Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke:the IAC study. J Neurol Neurosurg Psychiatry. 2021;92:1062&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8448925</ArticleId><ArticleId IdType="pubmed">33903185</ArticleId></ArticleIdList></Reference><Reference><Citation>Paciaroni M, Agnelli G, Caso V, et al. Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i>. 2019;50:2168-2174.</Citation><ArticleIdList><ArticleId IdType="pubmed">31234756</ArticleId></ArticleIdList></Reference><Reference><Citation>Paciaroni M, Agnelli G, Caso V, et al. Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke. 2019;50:2168&#x2013;2174.</Citation><ArticleIdList><ArticleId IdType="pubmed">31234756</ArticleId></ArticleIdList></Reference><Reference><Citation>Stretz C, Wu TY, Wilson D, et al. Ischaemic stroke in anticoagulated patients with atrial fibrillation. <i>J Neurol Neurosurg Psychiatry.</i> 2021;92:1164-1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">34446528</ArticleId></ArticleIdList></Reference><Reference><Citation>Stretz C, Wu TY, Wilson D, et al. Ischaemic stroke in anticoagulated patients with atrial fibrillation. J Neurol Neurosurg Psychiatry. 2021;92:1164&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">34446528</ArticleId></ArticleIdList></Reference><Reference><Citation>Best JG, Cardus B, Klijn CJM, et al. Antithrombotic dilemmas in stroke medicine:new data, unsolved challenges<i>. J Neurol Neurosurg Psychiatry.</i> 2022:jnnp-2020-325249.</Citation><ArticleIdList><ArticleId IdType="pubmed">35728935</ArticleId></ArticleIdList></Reference><Reference><Citation>Best JG, Cardus B, Klijn CJM, et al. Antithrombotic dilemmas in stroke medicine:new data, unsolved challenges. J Neurol Neurosurg Psychiatry. 2022:2020&#x2013;325249. jnnp.</Citation><ArticleIdList><ArticleId IdType="pubmed">35728935</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda S, Kaikita K, Akao M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. <i>N Engl J Med.</i> 2019;381:1103-1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">31475793</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda S, Kaikita K, Akao M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019;381:1103&#x2013;1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">31475793</ArticleId></ArticleIdList></Reference><Reference><Citation>Maarse M, Seiffge D, Fierro N, et al. Left atrial appendage occlusion versus standard of care in patients with atrial fibrillation and a prior thrombo-embolic event despite oral anticoagulant therapy:a propensity score matched comparison<i>. Eur Heart J.</i> 2022;43(Supplement_2).</Citation></Reference><Reference><Citation>Maarse M, Seiffge D, Fierro N, et al. Left atrial appendage occlusion versus standard of care in patients with atrial fibrillation and a prior thrombo-embolic event despite oral anticoagulant therapy:a propensity score matched comparison. Eur Heart J. 2022;43((Supplement_2))</Citation></Reference><Reference><Citation>Osmancik P, Herman D, Neuzil P, et al. 4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation. <i>J Am Coll Cardiol.</i> 2022;79:1-14.</Citation><ArticleIdList><ArticleId IdType="pubmed">34748929</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmancik P, Herman D, Neuzil P, et al. 4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation. J Am Coll Cardiol. 2022;79:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">34748929</ArticleId></ArticleIdList></Reference><Reference><Citation>Anduaga I, Affronti A, Cepas-Guill&#xe9;n P, et al. Non-Pharmacological Stroke Prevention in Atrial Fibrillation. <i>J Clin Med.</i> 2023;12:5524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10488500</ArticleId><ArticleId IdType="pubmed">37685589</ArticleId></ArticleIdList></Reference><Reference><Citation>Anduaga I, Affronti A, Cepas-Guill&#xe9;n P, et al. Non-Pharmacological Stroke Prevention in Atrial Fibrillation. J Clin Med. 2023;12:5524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10488500</ArticleId><ArticleId IdType="pubmed">37685589</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials:a consensus report from the Bleeding Academic Research Consortium. <i>Circulation.</i> 2011;123:2736-2747.</Citation><ArticleIdList><ArticleId IdType="pubmed">21670242</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials:a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736&#x2013;2747.</Citation><ArticleIdList><ArticleId IdType="pubmed">21670242</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzikas A, Holmes DR, Jr., Gafoor S, et al. Percutaneous left atrial appendage occlusion:the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. <i>Europace.</i> 2017;19:4-15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841559</ArticleId><ArticleId IdType="pubmed">27540038</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzikas A, Holmes DR, Jr, Gafoor S, et al. Percutaneous left atrial appendage occlusion:the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace. 2017;19:4&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841559</ArticleId><ArticleId IdType="pubmed">27540038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappetein AP, Head SJ, G&#xe9;n&#xe9;reux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation:the Valve Academic Research Consortium-2 consensus document. <i>J Am Coll Cardiol.</i> 2012;60:1438-1454.</Citation><ArticleIdList><ArticleId IdType="pubmed">23036636</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappetein AP, Head SJ, G&#xe9;n&#xe9;reux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation:the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60:1438&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pubmed">23036636</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale:implications for stroke clinical trials:a literature review and synthesis. <i>Stroke.</i> 2007;38:1091-1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">17272767</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale:implications for stroke clinical trials:a literature review and synthesis. Stroke. 2007;38:1091&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">17272767</ArticleId></ArticleIdList></Reference><Reference><Citation>Price MJ, Ellis CR, Nielsen-Kudsk JE, et al. Peridevice Leak After Transcatheter Left Atrial Appendage Occlusion:An Analysis of the Amulet IDE Trial. <i>JACC Cardiovasc Interv.</i> 2022;15:2127-2138.</Citation><ArticleIdList><ArticleId IdType="pubmed">36357016</ArticleId></ArticleIdList></Reference><Reference><Citation>Price MJ, Ellis CR, Nielsen-Kudsk JE, et al. Peridevice Leak After Transcatheter Left Atrial Appendage Occlusion:An Analysis of the Amulet IDE Trial. JACC Cardiovasc Interv. 2022;15:2127&#x2013;2138.</Citation><ArticleIdList><ArticleId IdType="pubmed">36357016</ArticleId></ArticleIdList></Reference><Reference><Citation>Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. <i>Europace.</i> 2020;22:184.</Citation><ArticleIdList><ArticleId IdType="pubmed">31504441</ArticleId></ArticleIdList></Reference><Reference><Citation>Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. Europace. 2020;22:184.</Citation><ArticleIdList><ArticleId IdType="pubmed">31504441</ArticleId></ArticleIdList></Reference><Reference><Citation>Masjuan J, Salido L, DeFelipe A, et al. Oral anticoagulation and left atrial appendage closure:a new strategy for recurrent cardioembolic stroke. <i>Eur J Neurol.</i> 2019;26:816-820.</Citation><ArticleIdList><ArticleId IdType="pubmed">30586229</ArticleId></ArticleIdList></Reference><Reference><Citation>Masjuan J, Salido L, DeFelipe A, et al. Oral anticoagulation and left atrial appendage closure:a new strategy for recurrent cardioembolic stroke. Eur J Neurol. 2019;26:816&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">30586229</ArticleId></ArticleIdList></Reference><Reference><Citation>Freixa X, Cruz-Gonz&#xe1;lez I, Regueiro A, et al. Left Atrial Appendage Occlusion as Adjunctive Therapy to Anticoagulation for Stroke Recurrence. <i>J Invasive Cardiol.</i> 2019;31:212-216.</Citation><ArticleIdList><ArticleId IdType="pubmed">31088992</ArticleId></ArticleIdList></Reference><Reference><Citation>Freixa X, Cruz-Gonz&#xe1;lez I, Regueiro A, et al. Left Atrial Appendage Occlusion as Adjunctive Therapy to Anticoagulation for Stroke Recurrence. J Invasive Cardiol. 2019;31:212&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">31088992</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Gonz&#xe1;lez I, Gonz&#xe1;lez-Ferreiro R, Freixa X, et al. Left atrial appendage occlusion for stroke despite oral anticoagulation (resistant stroke). Results from the Amplatzer Cardiac Plug registry. <i>Rev Esp Cardiol</i>. 2020;73:28-34.</Citation><ArticleIdList><ArticleId IdType="pubmed">31036510</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Gonz&#xe1;lez I, Gonz&#xe1;lez-Ferreiro R, Freixa X, et al. Left atrial appendage occlusion for stroke despite oral anticoagulation (resistant stroke). Results from the Amplatzer Cardiac Plug registry. Rev Esp Cardiol. 2020;73:28&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">31036510</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>